Nuvectis Pharma Inc
For the period ended Dec 31, 2024. Filed Feb 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 25, 2025
NVCT$21.08+0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
(a)Financial Statements.
The following financial statements are filed as part of this report:
| | | |
|---|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID#1309) | F-2 | |
| Financial Statements: | | |
| Balance Sheets as of December 31, 2024 and 2023 | | F-3 |
| Statements of Operations for the Years Ended December 31, 2024 and 2023 | | F-4 |
| Statements of Changes in Shareholders’ equity for the Years Ended December 31, 2024 and 2023 | | F-5 |
| Statements of Cash Flows for the Years Ended December 31, 2024 and 2023 | | F-6 |
| Notes to Financial Statements | | F-7 - F-24 |
NUVECTIS PHARMA INC.
INDEX TO FINANCIAL STATEMENTS
U.S. DOLLARS
| | | |
|---|---|---|
| | Page | |
| | | |
| REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB name: Kesselman & Kesselman C.P.A.s and PCAOB ID: 1309) | | F-2 |
| FINANCIAL STATEMENTS: | | |
| Balance Sheets | | F-3 |
| Statements of Operations | | F-4 |
| Statements of Changes in Shareholders’ equity | | F-5 |
| Statements of Cash Flows | | F-6 |
| Notes to the Financial Statements | | F-7 - F-24 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.